Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

Diagnostic Microbiology and Infectious Disease

Volumn 63, Issue 1, 2009, Pages 38-42

  Ambrose, Paul G ^a   Meagher, Alison K ^b   Passarell, Julie A ^b   Wart, Scott A Van ^a   Cirincione, Brenda B ^b   Rubino, Chris M ^a   Korth Bradley, Joan M ^c   Babinchak, Timothy ^c   Ellis Grosse, Evelyn ^c  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b Albany Medical College   (United States)

^c PFIZER INC   (United States)

Author keywords

Enterobacteriaceae; Pharmacokinetic pharmacodynamic; Susceptibility breakpoints; Tigecycline

Indexed keywords

TIGECYCLINE;

ABDOMINAL INFECTION; ANTIBIOTIC SENSITIVITY; ARTICLE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; SKIN DISEASES, BACTERIAL;

EID: 57349161892     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.09.014     Document Type: Article

References (12)

1. Ambrose P.G. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future. Pharmacother 25 (2006) 129-134
2. Drusano G.L., Preston S.L., Hardalo C., Hare R., Banfield C., Andes D., Vesga O., and Craig W.A. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45 (2001) 13-22
3. Dudley M.N., and Ambrose P.G. Pharmacodynamics in the study of drug resistance and setting of in vitro susceptibility breakpoints: ready for prime time. Current. Opin. Microbiol. 3 (2000) 515-521
4. Marchant C.D., Carlin S.A., Johnson C.E., and Shurin P.A. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon". J. Pediat. 120 (1992) 72-77
5. Meagher AK, Passarell JA, Liolios K, Van Wart Sam Cirincione BB, Ambrose PG (2005) Estimation of in vitro susceptibility breakpoints for tigecycline against Enterobacteriaceae. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, American Society for Microbiology, page 22, A-1156.
6. Morosini M.I., Garcia-Castillo M., Coque T.M., Valverde A., Novais A., Loza E., Baquero F., and Canton R. Antibiotic co-resistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50 (2006) 2695-2699
7. Oliva M.E., Rekha A., Yellin A., Pasternak J., Campos M., Rose G.M., Babinchak T., Ellis-Grosse E.J., Loh E., and 301 Study Group. A multi-center trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744. BMC. Infect. Dis. 5 (2005) 88
8. Passarell JA, Liolios K, Meagher AK, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG (2005) Exposure-response analysis of the efficacy of tigecycline in patients with complicated intra-abdominal infections. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, American Society for Microbiology, page 22, A-1155.
9. Sader H.S., Jones R.N., Stilwell M.G., Dowzicky M.J., and Fritsche T.R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52 (2005) 181-186
10. Solomkin J.S., Mazuski J.E., Baron E.J., Sawyer R.G., Nathens A.B., DiPiro J.T., Buchman T., Dellinger E.P., Jernigan J., Gorbach S., Chow A.W., and Bartlett J. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 39 (2003) 997-1005
11. Van Wart S.A., Owen J.S., Ludwig E.A., Meagher A.K., Korth-Bradley J.M., and Cirincione B.B. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob. Agents. Chemother. 50 (2006) 3701-3707
12. Wikler W.A., and Ambrose P.G. The breakpoint. In: Lorian V. (Ed). Antibiotics in laboratory medicine (2005), Lippincott Williams and Wilkins, Philadelphia 1-7